Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with
recurrent or metastatic head and neck cancer. Akt inhibitor MK2206 may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.